Dataset Information

Life Science's Average Publishable Unit (APU) Has Increased over the Past Two Decades.

ABSTRACT: Quantitative analysis of the scientific literature is important for evaluating the evolution and state of science. To study how the density of biological literature has changed over the past two decades we visually inspected 1464 research articles related only to the biological sciences from ten scholarly journals (with average Impact Factors, IF, ranging from 3.8 to 32.1). By scoring the number of data items (tables and figures), density of composite figures (labeled panels per figure or PPF), as well as the number of authors, pages and references per research publication we calculated an Average Publishable Unit or APU for 1993, 2003, and 2013. The data show an overall increase in the average ± SD number of data items from 1993 to 2013 of approximately 7±3 to 14±11 and PPF ratio of 2±1 to 4±2 per article, suggesting that the APU has doubled in size over the past two decades. As expected, the increase in data items per article is mainly in the form of supplemental material, constituting 0 to 80% of the data items per publication in 2013, depending on the journal. The changes in the average number of pages (approx. 8±3 to 10±3), references (approx. 44±18 to 56±24) and authors (approx. 5±3 to 8±9) per article are also presented and discussed. The average number of data items, figure density and authors per publication are correlated with the journal's average IF. The increasing APU size over time is important when considering the value of research articles for life scientists and publishers, as well as, the implications of these increasing trends in the mechanisms and economics of scientific communication.

SUBMITTER: Cordero RJ

PROVIDER: S-EPMC4911092 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Acupuncture has already been extensively utilized to treat high blood pressure (hypertension) in several nations. Nevertheless, the bibliometric research on the worldwide usage of acupuncture for hypertension is mostly unclear. As a result, our objective for the research aimed to investigate the present state as well as developments in the global usage of acupuncture on hypertension during the last 20 years using CiteSpace (5.8.R2). The Web of Science (WOS) database examined papers on acupuncture treatment of hypertension from 2002 to 2021. We examined the number of publications, cited journals, nations/regions, organizations, authors, cited authors, cited references, and keywords utilizing CiteSpace. The record of 296 documents was obtained between 2002 and 2021. The quantity and frequency of annual publications rose gradually. Regarding frequency and centrality of citations, Circulation and Clin Exp Hypertens (Clinical and Experimental Hypertension) scored top and second respectively. China had the most publications among countries/regions, as well as the five largest institutions were also in China. Cunzhi Liu was the most productive author, while P Li was the most referenced author. XF Zhao produced the first article inside the quantity of cited references classification. 'Electroacupuncture' had a significant frequency with centrality for the keywords, which suggested electroacupuncture is a popular treatment in this field. In the treatment of hypertension, electroacupuncture has a beneficial effect on reducing blood pressure. However, because of the many different applications of electroacupuncture frequencies in research, whether the electroacupuncture frequency is connected to the therapeutic impact should be given more significant consideration. The findings of this bibliometric analysis give an overview of the present state as well as developments of clinical studies on acupuncture for hypertensive patients during the last two decades, which could assist researchers in identifying hot subjects and exploring novel directions in further study within the field.

Project description:For pharmaceutical companies, it is essential to define their long-term corporate strategy. This especially involves the pipeline progress of pharmaceuticals and portfolio management. The objective of this study was to give a broad overview of study durations of the clinical trials from the top 30 pharmaceutical companies worldwide and to investigate what could possibly impact these study durations (e.g., indication areas, companies themselves, etc.) We worked with the clinicaltrials.gov database to examine the pipeline (phase 1-3) and portfolio (after regulatory approval) of the top 30 pharma companies worldwide over 20 years (from 2000-2020). We further calculated the study duration of each clinical study as the difference between the start date and end date. To analyze changes in our measure we estimated multiple linear regression to evaluate the impact of indication areas and companies on the study duration. Most of the clinical studies were conducted in the areas of ONCIM (N = 2720), and META (N = 1993). The indication with the highest study duration was ONCIM (on average 3.9 years per clinical study, SD: 0.8). Values for the study duration vary widely across companies. Mostly they range between 1 and 4 years (e.g., Merck Sharp & Dohme (MSD) on average 2.2 years per clinical study, SD: 1.0). Correlation analysis showed that study phases were positively correlated with the study duration (+ 0.36, p < 0.000), i.e., the higher the study phase, the higher the study duration. Furthermore, we found that indication areas influenced the study duration significantly (+ 0.17, p < 0.000). However, there were wide variations in effect sizes across indications. The results suggest that different indication areas influence the study duration to different extents. Pipeline progress and portfolio management differ widely between indications, companies and over the years. Research findings could help corporate strategy managers to make more informed decisions regarding their business development strategy.

Dataset Information

Life Science's Average Publishable Unit (APU) Has Increased over the Past Two Decades.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets